abrdn plc Sells 102,639 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)

abrdn plc cut its holdings in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 31.4% during the fourth quarter, Holdings Channel reports. The fund owned 224,356 shares of the biopharmaceutical company’s stock after selling 102,639 shares during the quarter. abrdn plc’s holdings in Abeona Therapeutics were worth $1,250,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in Abeona Therapeutics by 74.2% during the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 28,606 shares during the period. Geode Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 21.7% during the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Abeona Therapeutics during the 3rd quarter worth about $160,000. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics during the 3rd quarter worth about $84,000. Finally, Western Standard LLC grew its stake in Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Analyst Upgrades and Downgrades

ABEO has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a report on Monday, November 25th. Finally, StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $5.82 on Tuesday. The firm has a 50-day moving average price of $5.67 and a two-hundred day moving average price of $5.76. Abeona Therapeutics Inc has a 12-month low of $3.05 and a 12-month high of $9.01. The company has a market capitalization of $253.00 million, a P/E ratio of -2.16 and a beta of 1.43. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.